Info

StemCells, Inc. is a biopharmaceutical company. The Company is engaged in the discovery and development of cell-based therapeutics to treat damage to, or degeneration of, major organ systems. The Company has product development programs for two cell types: the human neural stem cell and human liver engrafting cells. In its CNS Program, the Company is conducting a Phase I clinical trial to evaluate the safety and preliminary efficacy of its HuCNS-SC product candidate (purified human neural stem cells) as a treatment for infantile and late infantile neuronal ceroid lipofuscinosis (NCL), two forms of a group of disorders often referred to as Batten disease. In addition, it is conducting preclinical work for spinal cord injury, myelin disorders and retinal disorders. In its Liver Program, the Company is in preclinical development with, and is continuing to improve processes to isolate and purify, its human liver engrafting cells (hLEC).(Source: 10-K)